28538498|t|Ghrelin Protects the Thymic Epithelium From Conditioning-Regimen - Induced Damage and Promotes the Restoration of CD4+ T Cells in Mice After Bone Marrow Transplantation
28538498|a|The delay in immune reconstitution after hematopoietic stem cell transplantation (HSCT), especially a delay in central immune reconstitution, leads to opportunistic infections and disease relapse after transplantation and affects the long-term outcome of HSCT. This delay is mainly attributable to thymic damage after myeloablative chemotherapy and radiotherapy METHODS: We established a model of allogeneic bone marrow transplantation (BMT) in mice and administered ghrelin (GRL) 7 days before the conditioning regimen or the day after BMT. All the GRL - treated mice, especially those administered GRL prior to the conditioning regimen, exhibited more intact thymic architecture and a more rapid restoration of CD4 T lymphocytes after BMT than those of the corresponding control mice. Moreover, the levels of T cell receptor excision circles (TRECs) were significantly higher in the mice treated with GRL prior to the conditioning regimen than in the control mice at 28 days after BMT. Our finding s suggest that GRL may be a novel potential therapeutic approach to protecting the thymic epithelium from conditioning-regimen - induced damage and promoting rapid and durable thymic and peripheral CD4 T cell recovery after HSCT.
28538498	0	7	Ghrelin	T103	UMLS:C0911014
28538498	21	38	Thymic Epithelium	T017	UMLS:C0229951
28538498	44	64	Conditioning-Regimen	T058	UMLS:C0376450
28538498	99	110	Restoration	T058	UMLS:C1283255
28538498	114	126	CD4+ T Cells	T017	UMLS:C0039215
28538498	130	134	Mice	T204	UMLS:C0026809
28538498	141	168	Bone Marrow Transplantation	T058	UMLS:C0005961
28538498	182	203	immune reconstitution	T033	UMLS:C1960768
28538498	210	249	hematopoietic stem cell transplantation	T058	UMLS:C0472699
28538498	251	255	HSCT	T058	UMLS:C0472699
28538498	288	309	immune reconstitution	T038	UMLS:C1096197
28538498	320	344	opportunistic infections	T038	UMLS:C0029118
28538498	349	364	disease relapse	T038	UMLS:C0277556
28538498	371	386	transplantation	T058	UMLS:C0040732
28538498	424	428	HSCT	T058	UMLS:C0472699
28538498	467	480	thymic damage	T037	UMLS:C3897359
28538498	487	513	myeloablative chemotherapy	T058	UMLS:C1513784
28538498	518	530	radiotherapy	T058	UMLS:C1522449
28538498	577	604	bone marrow transplantation	T058	UMLS:C0005961
28538498	606	609	BMT	T058	UMLS:C0005961
28538498	614	618	mice	T204	UMLS:C0026809
28538498	636	643	ghrelin	T103	UMLS:C0911014
28538498	645	648	GRL	T103	UMLS:C0911014
28538498	668	688	conditioning regimen	T058	UMLS:C0376450
28538498	706	709	BMT	T058	UMLS:C0005961
28538498	719	722	GRL	T103	UMLS:C0911014
28538498	733	737	mice	T204	UMLS:C0026809
28538498	769	772	GRL	T103	UMLS:C0911014
28538498	786	806	conditioning regimen	T058	UMLS:C0376450
28538498	830	836	thymic	T017	UMLS:C0040113
28538498	867	878	restoration	T058	UMLS:C1283255
28538498	882	899	CD4 T lymphocytes	T017	UMLS:C0039215
28538498	906	909	BMT	T058	UMLS:C0005961
28538498	950	954	mice	T204	UMLS:C0026809
28538498	980	1012	T cell receptor excision circles	T103	UMLS:C1515131
28538498	1014	1019	TRECs	T103	UMLS:C1515131
28538498	1054	1058	mice	T204	UMLS:C0026809
28538498	1059	1071	treated with	T058	UMLS:C0332293
28538498	1072	1075	GRL	T103	UMLS:C0911014
28538498	1089	1109	conditioning regimen	T058	UMLS:C0376450
28538498	1130	1134	mice	T204	UMLS:C0026809
28538498	1152	1155	BMT	T058	UMLS:C0005961
28538498	1161	1168	finding	T033	UMLS:C0243095
28538498	1184	1187	GRL	T103	UMLS:C0911014
28538498	1252	1258	thymic	T017	UMLS:C0040113
28538498	1259	1269	epithelium	T017	UMLS:C0014609
28538498	1275	1295	conditioning-regimen	T058	UMLS:C0376450
28538498	1345	1351	thymic	T017	UMLS:C0040113
28538498	1356	1366	peripheral	T082	UMLS:C0205100
28538498	1367	1377	CD4 T cell	T017	UMLS:C0039215
28538498	1378	1386	recovery	T038	UMLS:C2004454
28538498	1393	1397	HSCT	T058	UMLS:C0472699